LLY
1,021.76
-0.21%↓
JNJ
199.29
+1.67%↑
ABBV
233.81
+0.62%↑
UNH
320.41
-0.3%↓
AZN
89.34
+0.22%↑
LLY
1,021.76
-0.21%↓
JNJ
199.29
+1.67%↑
ABBV
233.81
+0.62%↑
UNH
320.41
-0.3%↓
AZN
89.34
+0.22%↑
LLY
1,021.76
-0.21%↓
JNJ
199.29
+1.67%↑
ABBV
233.81
+0.62%↑
UNH
320.41
-0.3%↓
AZN
89.34
+0.22%↑
LLY
1,021.76
-0.21%↓
JNJ
199.29
+1.67%↑
ABBV
233.81
+0.62%↑
UNH
320.41
-0.3%↓
AZN
89.34
+0.22%↑
LLY
1,021.76
-0.21%↓
JNJ
199.29
+1.67%↑
ABBV
233.81
+0.62%↑
UNH
320.41
-0.3%↓
AZN
89.34
+0.22%↑
24u
Huidig
Min
365.73
Max
384.76
Inkomsten | 31M 125M |
|---|---|
Verkoop | 97M 1.4B |
Winstmarge | 8.84 |
Aanbevelingen | Strong Buy |
|---|---|
12 Maanden Prognose | +6.9% upside |
Marktkapitalisatie | 22B |
|---|---|
Vorige openingsprijs | 372.49 |
Vorige sluitingsprijs | 375.03 |
By Acuity
50%
50%
152 / 374 Rangschikking in Healthcare
Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.
17 nov 2025, 12:16 UTC
Zymeworks, Jazz Pharmaceuticals Shares Rise Following Positive Phase 3 Results for Cancer Treatment
DJ
Lezen
12 mei 2025, 02:16 UTC
Asia Pharma Stocks Fall After Trump's Plan to Cut Drug Costs
DJ
Lezen
29 jan 2025, 15:59 UTC
ImmunityBio Shares Rise After Collaboration, Supply Agreement With BeiGene
DJ
Lezen
27 nov 2024, 15:22 UTC
BeiGene Shares Up on EU Approval for Gastric, Esophageal Cancer Treatment
DJ
Lezen
21 nov 2024, 14:45 UTC
Zymeworks Shares Rise 8.3% After Licensed Cancer Treatment Gets FDA OK
DJ
Lezen
6 nov 2025, 11:01 UTC
BeOne Medicines Sees FY25 Rev $5.1B-$5.3B >ONC
DJ
Lezen
6 nov 2025, 11:01 UTC
BeOne Medicines 3Q Adj EPS $2.65 >ONC
DJ
Lezen
6 nov 2025, 11:01 UTC
BeOne Medicines 3Q Rev $1.4B >ONC
DJ
Lezen
6 nov 2025, 11:00 UTC
BeOne Medicines 3Q EPS $1.09 >ONC
DJ
Lezen
6 aug 2025, 10:01 UTC
BeOne Medicines Narrows FY25 View To Rev $5.0B-$5.3B >ONC
DJ
Lezen
6 aug 2025, 10:01 UTC
BeOne Medicines 2Q Rev $1.3B >ONC
DJ
Lezen
6 aug 2025, 10:01 UTC
BeOne Medicines 2Q Adj EPS $2.25 >ONC
DJ
Lezen
6 aug 2025, 10:00 UTC
BeOne Medicines 2Q EPS 84c >ONC
DJ
Lezen
9 jul 2025, 09:17 UTC
Stocks to Watch Wednesday: Freeport-McMoRan, Glencore, Novo Nordisk -- WSJ
DJ
Lezen
7 mei 2025, 10:07 UTC
BeiGene Maintains 2025 Expense Guidance of $4.1B to $4.4B >ONC
DJ
Lezen
7 mei 2025, 10:06 UTC
BeiGene Backs 2025 Rev $4.9B-$5.3B >ONC
DJ
Lezen
7 mei 2025, 10:05 UTC
BeiGene 1Q Net $1.27M >ONC
DJ
Lezen
7 mei 2025, 10:04 UTC
BeiGene Says to Rename Company to BeOne Medicines >ONC
DJ
Lezen
7 mei 2025, 10:02 UTC
BeiGene 1Q EPS $0.00 >ONC
DJ
Lezen
7 mei 2025, 10:02 UTC
BeiGene 1Q Rev Increased 49% >ONC
DJ
Lezen
7 mei 2025, 10:00 UTC
BeiGene 1Q Rev $1.12B >ONC
DJ
Lezen
27 feb 2025, 11:07 UTC
BeiGene Sees 2025 Rev $4.9B-$5.3B >ONC
DJ
Lezen
27 feb 2025, 11:06 UTC
BeiGene 4Q Global BRUKINSA Rev of $828M >ONC
DJ
Lezen
27 feb 2025, 11:06 UTC
BeiGene 4Q Loss/Shr 11c >ONC
DJ
Lezen
27 feb 2025, 11:06 UTC
BeiGene 4Q Rev $1.13B >ONC
DJ
Lezen
Prijswijziging
By TipRanks
12 Maanden Prognose
Gemiddelde 391.06 USD 6.9%
Hoogste 424 USD
Laagste 362 USD
Gebaseerd op 11 Wall Street-analisten die 12-maands prijsdoelen bieden voor BeOne Medicines Ltd ADR - Dist. in de afgelopen 3 maanden.
By TipRanks
Strong Buy
11 ratings
10
Buy
1
Hold
0
Sell
Gebaseerd op 11 analisten die aandelenratings hebben gegeven aan BeOne Medicines Ltd ADR - Dist in de afgelopen 3 maanden.
By Acuity
Nieuwssentiment
Neutral
Volatiliteit
Onder gemiddelde
Nieuws Volume (RCV)
Onder gemiddelde
Verkoop- en administratiekosten
Winst voor belastingen
Verkoop
Kosten van verkopen
Brutowinst op verkopen
Operationele winst
$